{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T03:15:28Z","timestamp":1648955728921},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Guidelines for referral to cancer genetics service for women diagnosed with triple negative breast cancer have changed over time. This study was conducted to assess the changing referral patterns and outcomes for women diagnosed with triple negative breast cancer across three regional cancer centres during the years 2014\u20132018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Following ethical approval, a retrospective electronic medical record review was performed to identify those women diagnosed with triple negative breast cancer, and whether they were referred to a genetics service and if so, the outcome of that genetics assessment and\/or genetic testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 2441 women with newly diagnosed breast cancer seen at our cancer services during the years 2014\u20132018, of whom 237 women were diagnosed with triple negative breast cancer. Based on age of diagnosis criteria alone, 13% (31\/237) of our cohort fulfilled criteria for genetic testing, with 81% (25\/31) being referred to a cancer genetics service. Of this group 68% (21\/31) were referred to genetics services within our regions and went on to have genetic testing with 10 pathogenic variants identified; 5x <jats:italic>BRCA1<\/jats:italic>, 4x <jats:italic>BRCA2<\/jats:italic> and \u00d7\u20091 <jats:italic>ATM<\/jats:italic>:c.7271\u2009T\u2009&gt;\u2009G.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Referral pathways for women diagnosed with TNBC to cancer genetics services are performing well across our cancer centres. We identified a group of women who did not meet eligibility criteria for referral at their time of diagnosis, but would now be eligible, as guidelines have changed. The use of cross-discipline retrospective data reviews is a useful tool to identify patients who could benefit from being re-contacted over time for an updated cancer genetics assessment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-021-00176-z","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T10:08:40Z","timestamp":1614334120000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia"],"prefix":"10.1186","volume":"19","author":[{"given":"Lucie G.","family":"Hallenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Westhuyzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T. J.","family":"Last","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julan V.","family":"Amalaseelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehnarz","family":"Salindera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan D.","family":"Spigelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Shakespeare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel J.","family":"Aherne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"176_CR1","volume-title":"Cancer in Australia 2019","author":"Australian Institute of Health and Welfare 2019","year":"2019","unstructured":"Australian Institute of Health and Welfare 2019. Cancer in Australia 2019. Canberra: AIHW; 2019."},{"issue":"15 Pt 1","key":"176_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"176_CR3","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787\u201395.","journal-title":"Cancer."},{"key":"176_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543\u201361.","journal-title":"Clin Epidemiol"},{"issue":"15","key":"176_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, et al. Genetic testing and results in a population-based cohort of breast Cancer patients and ovarian Cancer patients. J Clin Oncol. 2019;37(15):1305\u201315. https:\/\/doi.org\/10.1200\/JCO.18.01854.","journal-title":"J Clin Oncol"},{"issue":"5","key":"176_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2560.","journal-title":"Clin Cancer Res"},{"key":"176_CR7","unstructured":"eviQ Cancer Treatments Online CIN. Referral guidelines for breast cancer risk assessment and consideration of genetic testing. Cancer Institute NSW; 2019. updated 01\/02\/2019. V.4: [Available from: https:\/\/www.eviq.org.au\/cancer-genetics\/referral-guidelines\/1620-referral-guidelines-for-breast-cancer-risk-as.]"},{"issue":"6","key":"176_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"issue":"4","key":"176_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdz012.","journal-title":"Ann Oncol"},{"issue":"23","key":"176_CR10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"Jama."},{"issue":"23","key":"176_CR11","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. Jama. 2018;319(23):2401\u20139. https:\/\/doi.org\/10.1001\/jama.2018.6228.","journal-title":"Jama."},{"issue":"3","key":"176_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","volume":"62","author":"MI Canto","year":"2013","unstructured":"Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley J-W, Kamel I, et al. International Cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339\u201347. https:\/\/doi.org\/10.1136\/gutjnl-2012-303108.","journal-title":"Gut."},{"key":"176_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/BCTT.S236483","volume":"12","author":"S Wen","year":"2020","unstructured":"Wen S, Manuel L, Doolan M, Westhuyzen J, Shakespeare TP, Aherne NJ. Effect of clinical and treatment factors on survival outcomes of triple negative breast Cancer patients. Breast Cancer (Dove Medical Press). 2020;12:27\u201335. https:\/\/doi.org\/10.2147\/BCTT.S236483.","journal-title":"Breast Cancer (Dove Medical Press)"},{"issue":"1","key":"176_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1108\/IJHG-09-2018-0045","volume":"24","author":"M Lu","year":"2019","unstructured":"Lu M, Spigelman AD. Adherence to referral guidelines: genetic testing in an Australian triple negative breast cancer (TNBC) cohort. Internat J Health Governance. 2019;24(1):6\u201318. https:\/\/doi.org\/10.1108\/IJHG-09-2018-0045.","journal-title":"Internat J Health Governance"},{"issue":"8","key":"176_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/djy106","volume":"110","author":"H Shimelis","year":"2018","unstructured":"Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast Cancer risk genes identified by multigene hereditary Cancer panel testing. J Natl Cancer Inst. 2018;110(8):855\u201362. https:\/\/doi.org\/10.1093\/jnci\/djy106.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"176_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721\u201330. https:\/\/doi.org\/10.1002\/cncr.30498.","journal-title":"Cancer."},{"issue":"4","key":"176_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304\u201311. https:\/\/doi.org\/10.1200\/JCO.2014.57.1414.","journal-title":"J Clin Oncol"},{"issue":"8","key":"176_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genetic Med. 2016;18(8):823\u201332. https:\/\/doi.org\/10.1038\/gim.2015.166.","journal-title":"Genetic Med"},{"issue":"19","key":"176_CR19","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.53.6607.","journal-title":"J Clin Oncol"},{"issue":"1","key":"176_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-017-3940-y","volume":"18","author":"JS Park","year":"2018","unstructured":"Park JS, Lee ST, Nam EJ, Han JW, Lee JY, Kim J, et al. Variants of cancer susceptibility genes in Korean BRCA1\/2 mutation-negative patients with high risk for hereditary breast cancer. BMC Cancer. 2018;18(1):83. https:\/\/doi.org\/10.1186\/s12885-017-3940-y.","journal-title":"BMC Cancer"},{"issue":"13","key":"176_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","volume":"34","author":"ER Thompson","year":"2016","unstructured":"Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol. 2016;34(13):1455\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"176_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/ejhg.2017.122","volume":"25","author":"D Carrieri","year":"2017","unstructured":"Carrieri D, Dheensa S, Doheny S, Clarke AJ, Turnpenny PD, Lucassen AM, et al. Recontacting in clinical practice: the views and expectations of patients in the United Kingdom. Eur J Hum Genet. 2017;25(10):1106\u201312. https:\/\/doi.org\/10.1038\/ejhg.2017.122.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"176_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/ejhg.2016.188","volume":"25","author":"D Carrieri","year":"2017","unstructured":"Carrieri D, Dheensa S, Doheny S, Clarke AJ, Turnpenny PD, Lucassen AM, et al. Recontacting in clinical practice: an investigation of the views of healthcare professionals and clinical scientists in the United Kingdom. Eur J Hum Genet. 2017;25(3):275\u20139. https:\/\/doi.org\/10.1038\/ejhg.2016.188.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"176_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41431-018-0285-1","volume":"27","author":"D Carrieri","year":"2019","unstructured":"Carrieri D, Howard HC, Benjamin C, Clarke AJ, Dheensa S, Doheny S, et al. Recontacting patients in clinical genetics services: recommendations of the European society of human genetics. Eur J Hum Genet. 2019;27(2):169\u201382. https:\/\/doi.org\/10.1038\/s41431-018-0285-1.","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"176_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41431-018-0131-5","volume":"26","author":"F Sirchia","year":"2018","unstructured":"Sirchia F, Carrieri D, Dheensa S, Benjamin C, Kayserili H, Cordier C, et al. Recontacting or not recontacting? A survey of current practices in clinical genetics centres in Europe. Eur J Hum Genet. 2018;26(7):946\u201354. https:\/\/doi.org\/10.1038\/s41431-018-0131-5.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"176_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/jgc4.1173","volume":"28","author":"L Sawyer","year":"2019","unstructured":"Sawyer L, Creswick H, Lewandowski R, Quillin J. Recontacting patients for multigene panel testing in hereditary cancer: efficacy and insights. J Genet Couns. 2019;28(6):1198\u2013207.","journal-title":"J Genet Couns"},{"key":"176_CR27","volume-title":"Clinical Genetics Service Standards Framework","author":"Human Genetics Society of Australasia","year":"2013","unstructured":"Human Genetics Society of Australasia. Clinical Genetics Service Standards Framework 2013. Available from: http:\/\/www.hgsa.org.au\/resources-policies-and-position-statements."},{"issue":"4","key":"176_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejmg.2017.11.017","volume":"61","author":"G Beunders","year":"2018","unstructured":"Beunders G, Dekker M, Haver O, Meijers-Heijboer HJ, Henneman L. Recontacting in light of new genetic diagnostic techniques for patients with intellectual disability: feasibility and parental perspectives. Eur Med Genet. 2018;61(4):213\u20138.","journal-title":"Eur Med Genet"},{"issue":"6","key":"176_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/ajo.12504","volume":"56","author":"HP Pokharel","year":"2016","unstructured":"Pokharel HP, Hacker NF, Andrews L. Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care. Aust N Z J Obstet Gynaecol. 2016;56(6):633\u20138.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"176_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jgc4.1041","volume":"28","author":"CA Attard","year":"2019","unstructured":"Attard CA, Carmany EP, Trepanier AM. Genetic counselor workflow study: the times are they a-changin\u2019? J Genet Couns. 2019;28(1):130\u201340.","journal-title":"J Genet Couns"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00176-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13053-021-00176-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00176-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T10:15:03Z","timestamp":1614334503000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-021-00176-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1186\/s13053-021-00176-z","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The work was reviewed by the North Coast New South Wales Health HREC and was deemed to be a quality assurance activity (reference: QA346).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}